share_log

Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target

Benzinga ·  Aug 14, 2023 10:11

Roth MKM analyst Jonathan Aschoff reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment